This was significant for the saRNA previous COVID-19 group when compared to either non-saRNA groups (CD8+:CD4+ ratio GM 0.3 (sd±5.1) and 0.1 (sd±11.8) in COVID-19 naïve and previously infected respectively) (Fig 4F). This evidence concerns the gene CD4 and COVID-19.